BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
June 13, 2003
View Archived Issues
Mouse Leukemic Virus, HIV Rank First, Second In Gene Therapy Sweepstakes - But Oops Factor!
Read More
Onyx Cuts Staff Further, Shifts Entire Focus To Bayer Program
Read More
InterMune Falls On Lowered Guidance; Reports Positive Data
Read More
Durect Seeking $50M Through Offering Of Convertible Notes
Read More
Northfield Gets Positive News On Blood Product; Hemosol Set Back
Read More
Other News To Note
Read More
Pozen Licenses Migraine Drug To GSK In Potential $160M Deal
Pozen Inc. could garner up to at least $160 million after entering a deal with GlaxoSmithKline plc surrounding a migraine treatment. (BioWorld Today)
Read More
Maxim Gets Back On Track After Reporting Positive Ceplene Data
Read More